Press Release Archives - Page 18 of 22

Spectral Medical Engages Crescendo Communications to Provide Investor Relations Services in the United States

TORONTO, CANADA — March 4, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

Spectral Medical to Participate at the Upcoming H.C. Wainwright Global Life Sciences Conference

TORONTO, CANADA – March 2, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform...

Spectral Medical Announces that its Wholly-Owned Subsidiary Dialco Medical has been Granted FDA IDE Authorization to Conduct a Trial of DIMI for Home Hemodialysis Use

TORONTO, Canada – February 23, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (“Dialco”), has been granted Investigational Device Exemption (IDE) authorization by the...

Spectral Medical Appoints Dr. John Kellum as Chief Medical Officer

TORONTO, CANADA – February 1, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the...

Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference

TORONTO, CANADA – January 11, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting...

Spectral Medical to Present at the SNN Network Canada Virtual Event on January 7, 2021

TORONTO, CANADA – January 6, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.